AAPL VS VTYX Stock Comparison

Performance

AAPL
100/100

AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.

VTYX
10/100

VTYX returned -90.88% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AAPL
78/100

38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.

VTYX

"Analyst Price Targets" not found for VTYX

Sentiment

AAPL
70/100

AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.

VTYX

"Sentiment" not found for VTYX

Technicals

AAPL
18/100

AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

VTYX
14/100

VTYX receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

AAPL
100/100

AAPL has missed earnings 1 times in the last 20 quarters.

VTYX
10/100

VTYX has missed earnings 7 times in the last 20 quarters.

Profit

AAPL
76/100

Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.

VTYX
10/100

Out of the last 13 quarters, VTYX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AAPL
45/100

AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

VTYX
44/100

VTYX has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Dividend

AAPL
50/100

AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.

VTYX

"Dividend" not found for VTYX

All score calculations are broken down here to help you make more informed investing decisions

Apple Inc. Summary

Nasdaq / AAPL

Technology

Consumer Electronics

Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.

Ventyx Biosciences, Inc. Common Stock Summary

Nasdaq / VTYX

Healthcare

Biotechnology

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Power up your portfolio